OncoZenge

6.17

SEK

+2.32 %

Less than 1K followers

ONCOZ

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Ownership

Investor consensus

+2.32%

-7.63%

+64.53%

+57.6%

-4.34%

+81.47%

-30.52%

-

-49.58%

OncoZenge is a Swedish pharmaceutical company that develops treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. After completing phase 2 studies, the company's product candidate is under further development as a basis for applying for regulatory market approvals and commercialization. OncoZenge is headquartered in Bromma.

Market cap

72.27M SEK

Turnover

900.17K SEK

Revenue

-

EBIT %

-

P/E

-

Dividend yield-%

-

Financial calendar

15/5

2025

Interim report Q1'25

28/5

2025

General meeting '25

21/8

2025

Interim report Q2'25

All

Press releases

3rd party

ShowingAll content types

Press releaseyesterday

Impala Nordic: OncoZenge - Europa-partner säkrad och kassan stärkt

Regulatory press releaseyesterday

OncoZenge AB enters exclusive agreement with Molteni Farmaceutici for commercialization of BupiZenge™ in Europe

Regulatory press releaseyesterday

OncoZenge AB har ingått exklusivt avtal med Molteni Farmaceutici för kommersialisering av BupiZenge™ i Europa

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Press release3/4/2025, 3:00 PM

OncoZenge AB erhåller ett positivt utlåtande gällande PCT-patentansökan för BupiZenge™

Press release3/4/2025, 3:00 PM

OncoZenge AB receives positive assessment regarding the PCT-patent application for BupiZenge™

Regulatory press release3/3/2025, 2:00 PM

Kommuniké från extra bolagsstämma i OncoZenge AB

Press release2/28/2025, 9:25 AM

OncoZenge AB presenterar på Life Science-dagen i Göteborg den 5 mars

Press release2/20/2025, 1:15 PM

Impala Nordic: OncoZenge - Rapportkommentar: Ett händelserikt kvartal lagt till handlingarna

Press release2/20/2025, 11:25 AM

Impala Nordic: OncoZenge - Rapportintervju med VD, Stian Kildal

Regulatory press release2/20/2025, 7:00 AM

OncoZenge AB bokslutskommuniké 2024

Press release1/31/2025, 10:35 AM

Impala Nordic: OncoZenge - Intervju med VD, Stian Kildal

Press release1/28/2025, 12:30 PM

Impala Nordic: OncoZenge - Säkrar finansiering av fas 3-studie

Regulatory press release1/28/2025, 7:00 AM

OncoZenge AB: KALLELSE TILL EXTRA BOLAGSSTÄMMA I ONCOZENGE AB (publ)

Regulatory press release1/27/2025, 6:00 PM

OncoZenge AB: OncoZenge ingår investeringsavtal om 30,2 miljoner SEK med nya strategiska investeraren Sichuan Yangtian Bio-Pharmaceutical, att genomföras genom riktade nyemissioner

Regulatory press release1/27/2025, 6:00 PM

OncoZenge AB: OncoZenge enters into SEK 30.2 million investment agreement with new strategic investor Sichuan Yangtian Bio-Pharmaceutical, intended to be carried out through directed share issues

Press release1/16/2025, 2:02 PM

OncoZenge AB lämnar in PCT-patentansökan för BupiZenge™

Press release1/16/2025, 2:02 PM

OncoZenge AB files PCT patent application for BupiZenge™

Press release1/14/2025, 12:00 PM

Impala Nordic: OncoZenge - Avser att ingå avtal för kommersialisering i Europa

Regulatory press release1/13/2025, 4:30 PM

OncoZenge AB har ingått ett icke-bindande avtal med avsikt att samarbeta med Molteni Farmaceutici för kommersialisering av BupiZenge™ i Europa

Regulatory press release1/13/2025, 4:30 PM

OncoZenge AB has entered into a non-binding agreement with the intention to partner with Molteni Farmaceutici for commercialization of BupiZenge™ in Europe

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.